Clinical trialEPhase 1Recruiting
A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- EPhase 1
- Status
- Recruiting
- Study type
- Interventional
- Start
- 1 June 2026
- Expected end
- 31 May 2027
- Enrollment
- 10 participants
- Sites
- 1
- Primary outcomes
- Absorbed radiation dose (Gy) distribution in normal organs and tumors by quantitative SPECT/CT dosimetry
- Sponsor
- Other
- Results posted
- No
- Last update
- 16 July 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This study is to evaluate the safety, biodistribution, radiation dosimetry and tumor uptake of the \[68Ga\]/ \[131I\]-IR199 in patients with Claudin 18.2 positive gastric cancer and pancreatic cancer.